Early antithrombotic therapy for another highly lethal viral pneumonia pandemic

Abstract

Viral respiratory infections have threatened humanity throughout history. Newly emerging and re-emerging diseases have spread with unprecedented speed and scale, thus posing a new challenge for reducing mortality before vaccines are made available. During the COVID-19 pandemic, antithrombotic therapy has achieved remarkable success and been a pivotal treatment in reducing mortality [1]. Whether the effect of antithrombotic therapy can be extended to other transmissible viral pneumonia is an interesting topic.